The general consensus is to start by diagnostic blocks; more than 50% pain relief in more than one block is considered an indication to proceed with RFA. It is well established that lumbar medial ...

The Food and Drug Administration (FDA) has granted Fast Track designation to BRTX-100 for the treatment of chronic lumbar disc disease, defined as back and/or radicular pain with confirmed ...

VIVEX Biologics, Inc. sponsored research reports positive outcomes for patients with chronic lumbar discogenic pain treated using a single intradiscal injection of VIA Disc NP, an allogeneic ...

BioRestorative Therapies Inc (NASDAQ: BRTX) has announced that the independent Data Safety Monitoring Board (DSMB), overseeing the company's ongoing Phase 2 trial to treat chronic lumbar ...

Lumbar magnetic resonance imaging (MRI) was performed at baseline, at 12 weeks (T 12), and after 24 weeks (T 24).

In October 2024, Dr. Cuéllar performed a three-level lumbar artificial disc replacement (ADR) using the ProDisc system. The procedure involved disc arthroplasty at the L3-4, L4-5, and L5-S1 levels.

BioRestorative Therapies Inc (NASDAQ: BRTX) announced that the final subject in its BRTX-100 Phase 2 trial safety cohort has been dosed.

In October 2024, Dr. Cuéllar performed a three-level lumbar artificial disc replacement (ADR) using the ProDisc system. The procedure involved disc arthroplasty at the L3-4, L4-5, and L5-S1 levels.